Dong-Keun Lee,
Research Scientist,
University Of California Los Angeles
Dr. Dong-Keun Lee received his Ph.D. from the Michigan State University in Chemistry and developed novel porous materials for applications in biomolecular separations and cancer research. He then started a postdoctoral fellowship at Northwestern University working on novel bioinspired adhesives for medical applications. At UCLA, Dr. Lee pioneered the development of nanodiamond-polymer complexes to address a spectrum of indications ranging from chemotherapy to bone growth and anti-infection. He is a recipient of the Chancellor's Postdoctoral Research Award, recognizing the top early career innovators at UCLA.
Phenotypic Personalized Medicine: Merging Nanomedicine with Engineering Optimization Platforms to Transform Combination Therapy
Monday, 28 September 2015 at 14:00
Add to Calendar ▼2015-09-28 14:00:002015-09-28 15:00:00Europe/LondonPhenotypic Personalized Medicine: Merging Nanomedicine with Engineering Optimization Platforms to Transform Combination TherapyPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Nanodiamonds have emerged as promising agents for drug delivery and imaging due to their unique surface properties. Nanodiamond-anthracycline compounds have mediated major improvements to drug delivery efficacy and safety. Most recently, NDX, a nanodiamond-doxorubicin agent, markedly enhanced the pre-clinical treatment efficacy of multiple drug-resistant tumor models with no apparent myelosuppression, demonstrating potent drug binding and the absence of early drug release. The combination of these pre-clinical advancements in diamond-based nanomedicine and nanodiamond surface properties serves as a foundation for a promising developmental roadmap that will be discussed. More recently, or team has focused on the integration of nano-modified and unmodified drug administration towards improved combination therapy via engineering optimization platforms. More specifically, we have developed a Phenotypic Personalized Medicine (PPM)-based platform for the mechanism-independent optimization of combination therapy towards a broad spectrum of diseases. The translational progress of the PPM platform will be highlighted.
Add to Calendar ▼2015-09-28 00:00:002015-09-30 00:00:00Europe/LondonPoint-of-Care Diagnostics and Global Health World CongressPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-09-28 14:00:002015-09-28 15:00:00Europe/LondonPhenotypic Personalized Medicine: Merging Nanomedicine with Engineering Optimization Platforms to Transform Combination TherapyPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
